TG Therapeutics (TGTX) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

TG Therapeutics Revenue Highlights

Latest Revenue (Y)

$233.66M

Latest Revenue (Q)

$83.88M

Main Segment (Y)

License Revenue

Main Geography (Y)

Worldwide

TG Therapeutics Revenue by Period

TG Therapeutics Revenue by Year

Date	Revenue	Change
2023-12-31	$233.66M	8290.02%
2022-12-31	$2.79M	-58.36%
2021-12-31	$6.69M	4300.66%
2020-12-31	$152.00K	-
2019-12-31	$152.00K	-
2018-12-31	$152.00K	-0.25%
2017-12-31	$152.38K	-
2016-12-31	$152.38K	-
2015-12-31	$152.38K	-
2014-12-31	$152.38K	-
2013-12-31	$152.38K	699.98%
2012-12-31	$19.05K	100.00%
2011-12-31	-	100.00%
2010-12-31	-	100.00%
2009-12-31	-	100.00%
2008-12-31	-	100.00%
2007-12-31	-	100.00%
2006-12-31	-	100.00%
2005-12-31	-	100.00%
2004-12-31	-	100.00%
2003-12-31	-	-100.00%
2002-12-31	$500.00K	-81.56%
2001-12-31	$2.71M	-49.39%
2000-12-31	$5.36M	346.58%
1999-12-31	$1.20M	-60.00%
1998-12-31	$3.00M	2900.00%
1997-12-31	$100.00K	-
1996-12-31	$100.00K	-

TG Therapeutics generated $233.66M in revenue during NA 2023, up 8290.02% compared to the previous quarter, and up 153725.00% compared to the same period a year ago.

TG Therapeutics Revenue by Quarter

Date	Revenue	Change
2024-09-30	$83.88M	14.17%
2024-06-30	$73.47M	15.74%
2024-03-31	$63.47M	44.35%
2023-12-31	$43.97M	-73.48%
2023-09-30	$165.81M	931.57%
2023-06-30	$16.07M	106.00%
2023-03-31	$7.80M	9653.75%
2022-12-31	$80.00K	-14.89%
2022-09-30	$94.00K	-84.18%
2022-06-30	$594.00K	-70.54%
2022-03-31	$2.02M	-13.14%
2021-12-31	$2.32M	14.33%
2021-09-30	$2.03M	31.39%
2021-06-30	$1.54M	94.83%
2021-03-31	$793.00K	1986.84%
2020-12-31	$38.00K	-
2020-09-30	$38.00K	-
2020-06-30	$38.00K	-
2020-03-31	$38.00K	-
2019-12-31	$38.00K	-
2019-09-30	$38.00K	-
2019-06-30	$38.00K	-
2019-03-31	$38.00K	-
2018-12-31	$38.00K	-
2018-09-30	$38.00K	-
2018-06-30	$38.00K	-
2018-03-31	$38.00K	-0.25%
2017-12-31	$38.09K	-0.00%
2017-09-30	$38.10K	0.00%
2017-06-30	$38.09K	-
2017-03-31	$38.09K	-
2016-12-31	$38.09K	-0.00%
2016-09-30	$38.10K	0.00%
2016-06-30	$38.09K	-
2016-03-31	$38.09K	-
2015-12-31	$38.09K	-0.00%
2015-09-30	$38.10K	0.00%
2015-06-30	$38.09K	-
2015-03-31	$38.09K	-
2014-12-31	$38.09K	-0.00%
2014-09-30	$38.10K	0.00%
2014-06-30	$38.09K	-
2014-03-31	$38.09K	-
2013-12-31	$38.09K	-0.00%
2013-09-30	$38.10K	0.00%
2013-06-30	$38.09K	-
2013-03-31	$38.09K	99.99%
2012-12-31	$19.05K	100.00%
2012-09-30	-	100.00%
2012-06-30	-	100.00%
2012-03-31	-	100.00%
2011-12-31	-	100.00%
2011-09-30	-	100.00%
2011-06-30	-	100.00%
2011-03-31	-	100.00%
2010-12-31	-	100.00%
2010-09-30	-	100.00%
2010-06-30	-	100.00%
2010-03-31	-	100.00%
2009-12-31	-	100.00%
2009-09-30	-	100.00%
2009-06-30	-	100.00%
2009-03-31	-	100.00%
2008-12-31	-	100.00%
2008-09-30	-	100.00%
2008-06-30	-	100.00%
2008-03-31	-	100.00%
2007-12-31	-	100.00%
2007-09-30	-	-

TG Therapeutics generated $83.88M in revenue during Q3 2024, up 14.17% compared to the previous quarter, and up 521.83% compared to the same period a year ago.

TG Therapeutics Revenue Breakdown

TG Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 23	Dec 22	Dec 21
Product	$92.00M	-	-
Other Revenue	$1.50M	-	-
License Revenue	$140.15M	-	-
License revenue	-	$152.00K	$152.00K
Product revenue, net	-	$2.63M	$6.54M

TG Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: License Revenue (59.98%), Product (39.38%), and Other Revenue (0.64%).

Quarterly Revenue by Product

Product/Service	Sep 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21
Product	$83.30M	$50.49M	$66.94M	$25.07M	$1.51M	$755.00K	-	-	-	-	-	-	-	-
License Revenue	$38.00K	$38.00K	-	-	-	-	-	-	-	-	-	-	-	-
Royalty	$229.00K	$33.00K	-	-	-	-	-	-	-	-	-	-	-	-
Other Revenue	$315.00K	$415.00K	-	-	-	-	-	-	-	-	-	-	-	-
Milestone	-	$12.50M	-	-	-	-	-	-	-	-	-	-	-	-
License	-	-	-	$140.75M	$38.00K	$38.00K	-	-	-	-	-	-	-	-
License revenue	-	-	-	-	$38.00K	$38.00K	$38.00K	$38.00K	$38.00K	$38.00K	$38.00K	$38.00K	-	-
Product revenue, net	-	-	-	-	$16.04M	$7.76M	$42.00K	$56.00K	$556.00K	$1.98M	$2.28M	$1.99M	-	-

TG Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Product (99.31%), Other Revenue (0.38%), Royalty (0.27%), and License Revenue (0.05%).

TG Therapeutics Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 23
International	$3.22M
Worldwide	$92.00M

TG Therapeutics's latest annual revenue breakdown by geography, as of Dec 23: Worldwide (96.62%), and International (3.38%).

TG Therapeutics Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
EXEL	Exelixis	$1.83B	$478.06M
TGTX	TG Therapeutics	$233.66M	$83.88M
BTAI	BioXcel Therapeutics	$1.38M	$1.10M
XFOR	X4 Pharmaceuticals	-	$560.00K
VKTX	Viking Therapeutics	-	-
PDSB	PDS Bio	-	-
MDGL	Madrigal Pharmaceuticals	-	$62.17M
TERN	Terns Pharmaceuticals	-	-
AKRO	Akero Therapeutics	-	-
HEPA	Hepion Pharmaceuticals	-	-

TGTX Revenue FAQ

What is TG Therapeutics’s yearly revenue?

TG Therapeutics's yearly revenue for 2023 was $233.66M, representing an increase of 8290.02% compared to 2022. The company's yearly revenue for 2022 was $2.78M, representing a decrease of -58.36% compared to 2021. TGTX's yearly revenue for 2021 was $6.69M, representing an increase of 4300.66% compared to 2020.

What is TG Therapeutics’s quarterly revenue?

TG Therapeutics's quarterly revenue for Q3 2024 was $83.88M, a 14.17% increase from the previous quarter (Q2 2024), and a -49.41% decrease year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $73.47M, a 15.74% increase from the previous quarter (Q1 2024), and a 357.05% increase year-over-year (Q2 2023). TGTX's quarterly revenue for Q1 2024 was $63.47M, a 44.35% increase from the previous quarter (Q4 2023), and a 713.46% increase year-over-year (Q1 2023).

What is TG Therapeutics’s revenue growth rate?

TG Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 3393.23%, and for the last 5 years (2019-2023) was 153625.00%.

What are TG Therapeutics’s revenue streams?

TG Therapeutics's revenue streams in c 23 are Product, Other Revenue, and License Revenue. Product generated $92M in revenue, accounting 39.38% of the company's total revenue Other Revenue generated $1.5M in revenue, accounting 0.64% of the company's total revenue License Revenue generated $140.15M in revenue, accounting 59.98% of the company's total revenue

What is TG Therapeutics’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of TG Therapeutics was License Revenue. This segment made a revenue of $140.15M, representing 59.98% of the company's total revenue.